TenNor Discloses TNP-2198 for the Treatment of H. pylori Infections in the Journal of Medicinal Chemistry February 18, 2022

TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a 1:1 molar mixture of the parent drugs and exhibits activity against strains resistant to both rifamycins and nitroimidazoles. A crystal structure of TNP-2198 bound to a Mycobacterium tuberculosis RNA polymerase transcription initiation complex reveals that the rifamycin portion of TNP-2198 binds to the rifamycin binding site on RNAP and the nitroimidazole portion of TNP-2198 interacts directly with the DNA template-strand in the RNAP active-center cleft, forming a hydrogen bond with a base of the DNA template strand. TNP-2198 is currently in Phase 2 clinical development for the treatment of Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis.

Link to the article： https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c02045

About TenNor Therapeutics

TenNor Therapeutics (6872.HK), incorporated in 2013, is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of June 30, 2026, TenNor Therapeutics had built a pipeline of eight innovative programs, including two Core Products, namely: rifasutenizol (TNP-2198), a multi-targeted conjugated new molecular entity (“NME”) candidate for the treatment of Helicobacter pylori infection when used in combination with amoxicillin and a proton pump inhibitor, as well as monotherapy for bacterial vaginosis and Clostridioides difficile (C. difficile) infection; and rifaquizinone (TNP-2092) injection, a triple-targeting NME candidate for the treatment of acute bacterial skin and skin structure infection and implant-associated bacterial infections (such as prosthetic joint infection, left ventricular assist device infection and catheter-related bloodstream infection).

For more information, please visit: www.tennortherapeutics.com